新入荷 再入荷

Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations - ILCN.org (ILCN/WCLC)

flash sale icon タイムセール
終了まで
00
00
00
999円以上お買上げで送料無料(
999円以上お買上げで代引き手数料無料
通販と店舗では販売価格や税表示が異なる場合がございます。また店頭ではすでに品切れの場合もございます。予めご了承ください。
新品 8500円 (税込)
数量

商品詳細情報

管理番号 新品 :844757482
中古 :844757482-1
メーカー 7594e2 発売日 2025-05-17 09:48 定価 10000円
カテゴリ

Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations - ILCN.org (ILCN/WCLC)

Real-World and Clinical Trial Validation of a Deep Learning Radiomic  Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced  Non–Small Cell Lung Cancer | JCO Clinical Cancer InformaticsReal-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer | JCO Clinical Cancer Informatics,Hyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts  response to radiotherapy in cervical cancer | European Radiology  Experimental | Full TextHyperpolarized [1-13C]-pyruvate MRS evaluates immune potential and predicts response to radiotherapy in cervical cancer | European Radiology Experimental | Full Text,Determining Adjuvant Therapy Through Recurrence Prediction: New  Investigations - ILCN.org (ILCN/WCLC)Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations - ILCN.org (ILCN/WCLC),KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as  first-line treatment for metastatic NSCLC: A multicenter phase 2 trial:  Cell Reports MedicineKN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial: Cell Reports Medicine

 

商品情報の訂正

このページに記載された商品情報に記載漏れや誤りなどお気づきの点がある場合は、下記訂正依頼フォームよりお願い致します。

訂正依頼フォーム

商品レビュー

レビューの投稿にはサインインが必要です